News

SVF Vaccines AB announces positive clinical safety and immunogenicity data following completion of the Phase 1 study of its universal Covid-19 vaccine, SVF-002. SVF-002 is a DNA vaccine that has been designed to elicit a broad neutralizing antibody response directed against the Spike (S) protein of SARS-CoV-2, the virus that causes Covid-19, as well as T cell responses against highly conserved components of the virus, the membrane protein (M) and the nucleoprotein (N). In preclinical studies, SVF-002 induced a strong antibody response to SARS-CoV-2, and broad T-cell responses against beta-coronaviruses, with similar levels of activity against SARS-CoV-2 and an unrelated coronavirus isolated from bats.

Read the full Pressrelease below
 

SVF Vaccines AB, formerly Svenska Vaccinfabriken Produktion AB, announces that the first subject has been dosed with its universal Covid-19 vaccine (SVF-002). SVF-002, which has been developed and evaluated by the Horizon 2020 funded OpenCorona project, has been designed to elicit a strong neutralizing antibody response directed against the Spike (S) protein of SARS-CoV-2, the virus that causes Covid-19. Neutralizing antibodies directed against the S protein are known to be correlated with protection against the disease. However the S protein is highly variable, allowing escape variants to emerge. Unlike approved Covid-19 vaccines, SVF-002 contains three different variants of the receptor binding domain of the spike in combination with two other viral proteins. The vaccine has been designed to induce both neutralizing antibodies and T-cell responses to parts of the virus that are genetically stable and capable of eliminating cells in which the virus is present. This is thought to be especially important for clearing infections in people whose antibody response to vaccination is poor. By directing this T-cell response against parts of the virus that are much more highly conserved, 

Read the full Press release below
 

SVF will be presenting some of the latest results from the hepatitis B and D therapeutic vaccine development at #EASL2022 #ILC2022 in London June 22-26, 2022.

The abstract is entitled “Heterologous prime-boost immunotherapy circumvents tolerance and induces broadly neutralizing antibodies that protects against hepatitis B and D co-infection and hepatitis D super-infection”.